Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Brainomix Ltd.. (4/3/18). "Press Release: Brainomix Secures £7m ($9.8m) Investment to Tackle Strokes with AI". Oxford.

Organisations Organisation Brainomix Ltd.
  Organisation 2 Boehringer Ingelheim Venture Fund (BIVF)
Products Product e-ASPECTS software (automating Alberta Stroke Program Early CT Score (ASPECTS) method)
  Product 2 venture capital
Index term Index term Brainomix–SEVERAL: investment, 201804 financing round £7m led by Parkwalk Advisors + incl BIVF + Chimera Partners + Oxford Univ
Person Person Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH)
     


Brainomix builds on partnership with Boehringer Ingelheim for AI-assisted fast treatment of stroke victims in latest venture round.


Brainomix, a medical imaging company using artificial intelligence (AI) for the fast diagnosis and treatment of stroke victims, has attracted £7m ($9.8m) of investment to bring its software to the global health care market.

Boehringer Ingelheim Venture Fund (BIVF), the corporate venture fund of the global pharmaceutical company Boehringer Ingelheim, a driving force in the field of stroke, joined the round, which was led by university investment veterans Parkwalk Advisors. Existing investors Chimera Partners and Oxford University Innovation Fund also participated.

Brainomix’s flagship software solution, e-ASPECTS, uses AI to provide a fast and standardised assessment of stroke patient CT scans, supporting quick and consistent treatment decisions by medical professionals, irrespective of their experience and expertise. The software works by automating the clinically-validated Alberta Stroke Program Early CT Score (ASPECTS) method. e-ASPECTS provides physicians with a clinical support tool that is designed to improve stroke treatment outcomes at much lower overall cost.

The injection of cash will allow Brainomix to further commercialise its intelligent medical imaging and workflow software solutions and expand its market penetration around the world.

Alastair Kilgour of Parkwalk Advisors said: ”We welcome Boehringer Ingelheim Venture Fund to the Brainomix investor group and look forward to continue to help management maintain its leadership in intelligent medical imaging for stroke around the world.”

Dr Frank Kalkbrenner, Managing Director of the Boehringer Ingelheim Venture Fund, said: “Brainomix is a cutting-edge technology company with superior expertise in innovative stroke care. We are very pleased to join the accomplished management team and this prestigious group of investors. We are looking forward to working with them on breakthrough improvements in stroke care. Their e-ASPECTS solution significantly supports physicians in the demanding acute care setting and is a step forward for fast and consistent stroke diagnosis.”

Dr Michalis Papadakis, Brainomix CEO, said: “We welcome Boehringer Ingelheim Venture Fund to our team of investors. Their tremendous expertise and heritage in stroke will complement the knowledge of our existing investors. Since we started as a spin-out of the University of Oxford we have become a global market leader, with our stroke decision support and workflow tools installed in many leading stroke centres in more than 16 countries. With this investment we will grow around the world and continuously expand Brainomix’s intelligent imaging software for acute stroke care and clinical trials.”


Contact information:
Laura Kerley
lkerley
@brainomix.com
+44 (0) 1865 582681


About Brainomix

Brainomix, a medical diagnostics software company, was founded in 2010 as a spin-out from the University of Oxford and is dedicated to improving outcomes for patients with neurological and cerebrovascular disorders. Brainomix is currently focusing on acute stroke. By developing and equipping physicians with world-class, artificial intelligence-based medical imaging software, Brainomix aims to help them in making life-saving treatment decisions by supporting the selection of the right treatment for the right stroke patient.

www.brainomix.com


About Parkwalk

Parkwalk invests in high growth, knowledge intensive companies seeking to develop and commercialise technology and innovation originating from UK universities, research intensive institutions and technology clusters.

Founded in 2009, Parkwalk is the largest EIS growth fund manager focused on university spin-outs, having raised over £180m to date and backed over 90 companies across its managed funds since inception.

The Parkwalk investment vehicles include the evergreen Parkwalk Opportunities Fund, the University of Cambridge Enterprise Funds, the University of Oxford Innovation Funds and the University of Bristol Enterprise Funds.

www.parkwalkadvisors.com

   
Record changed: 2018-04-08

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px

More documents for Brainomix Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px




» top